Novartis receives European Commission approval for Rhapsido skin disease drug

Novartis received European Commission approval for Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU). The regulatory clearance is a positive step for the drug’s commercial launch and expands Novartis’s cardiovascular/immunology portfolio. The news is supportive for the stock but is unlikely to drive a large near-term market move on its own.

Analysis

Novartis received European Commission approval for Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU). The regulatory clearance is a positive step for the drug’s commercial launch and expands Novartis’s cardiovascular/immunology portfolio. The news is supportive for the stock but is unlikely to drive a large near-term market move on its own.